Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions
Retinitis Pigmentosa
Interventions
BIOLOGICAL

Wharton's jelly derived mesenchymal stemcells

The WJ-MSCs suspension from the culture was delivered to the operating room by cold chain and used within 24 h. A total of 1.5 ml of the WJ-MSC suspension was immediately injected into the deep subtenon space of each eye.

DEVICE

Magnovision

Specifically designed helmets producing high-frequency repetitive electromagnetic stimulation (MagnovisionTM, Bioretina Biotechnology, Ankara, Türkiye) stimulated the retinas and visual pathways in both eyes.

Trial Locations (3)

06570

BioRetina, Ankara

06312

Ankara University Biotechnology Institute, Ankara

06000

Umut Arslan, Ankara

All Listed Sponsors
lead

Ankara Universitesi Teknokent

OTHER

NCT05800301 - Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision | Biotech Hunter | Biotech Hunter